¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"monoclonal hypothesis"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 7 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • monoclonal
    ´Ü¼¼Æ÷±º-, ´ÜŬ·Ð-
  • monoclonal antibody
    ´ÜŬ·ÐÇ×ü
  • monoclonal gammopathy
    ´Ü¼¼Æ÷±º°¨¸¶±Û·ÎºÒ¸°º´Áõ
  • hypothesis
    °¡¼³
  • lattice hypothesis
    °ÝÀÚ°¡¼³
  • null hypothesis
    ¿µ°¡¼³, ±Í¹«°¡¼³
  • unitarian hypothesis
    Ç×üµ¿Àϰ¡¼³
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • hypothesis
    °¡¼³
  • null hypothesis
    ±Í¹«°¡¼³, ¿µ°¡¼³
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • monoclonal hypothesis
    ´ÜÀÏŬ·Ð°¡¼³
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • monoclonal antibody
    ´ÜŬ·ÐÇ×ü
  • monoclonal immunoglobulin detection
    ´ÜÀÏŬ·Ð¸é¿ª±Û·ÎºÒ¸°°ËÃâ
  • monoclonal gammopathy
    ´Ü¼¼Æ÷±º°¨¸¶±Û·ÎºÒ¸°º´Áõ
  • monoclonal
    ´Ü¼¼Æ÷±º-, Çѹ«¸®-
  • blending hypothesis
    À¶ÇÕÀ¯Àü¼³
  • central plasticity hypothesis
    ÁßÃßÀ¯¿¬¼º°¡¼³
  • countercurrent hypothesis
    ¿ª·ù°¡¼³
  • drift hypothesis
    À̵¿°¡¼³
  • dual recognition hypothesis
    Ç׿øÀÌÁßÀÎÁö°¡¼³
  • estrogen window hypothesis
    ¿¡½ºÆ®·Î°Õâ°¡¼³
  • expectation hypothesis
    ¿¹Ãø°¡¼³
  • hypothesis
    °¡¼³
  • hypoxia-selectivity hypothesis
    Àú»ê¼ÒÁõ¼±Åõµ°¡¼³
  • lattice hypothesis
    °ÝÀÚ°¡¼³
  • lipid hypothesis
    ÁöÁú°¡¼³
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 7 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • antibody, monoclonal
    ´Ü¼¼Æ÷±ºÇ×ü, Çѹ«¸®Ç×ü
  • antibody,monoclonal
    ´ÜŬ·Ð¼º(Ó¤¡­àõ)
  • Glucostatic hypothesis, of appetite regulation
    Ç×´ç±â¼³(ù÷ÓØÐñæò), ½Ä¿åÁ¶Àý(ãÝé¯ðàï½)
  • Lyon s hypothesis
    ¶óÀ̿°¡¼³.
  • Starling s hypothesis
    ½ºÅ¸¾Ë¸µ°¡¼³.
  • hypothesis, lattice
    °ÝÀÚ¼³
  • receptor hypothesis
    ¼ö¿ëü°¡¼³
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • atherosclerosis,monoclonal hypothesis
    ´ÜÀÏŬ·Ð¼º°¡¼³(Ó¤ìé¡­Ê£àã)
  • antibody, monoclonal
    ´Ü¼¼Æ÷±ºÇ×ü, Çѹ«¸®Ç×ü
  • antibody,monoclonal
    ´ÜŬ·Ð¼º(Ó¤¡­àõ)
  • monoclonal
    ´ÜÀÏŬ·Ð¼º, ´ÜÀϼ¼Æ÷±ºÀÇ.
  • monoclonal
    ´ÜÀÏŬ·Ð¼º, ´ÜÀϼ¼Æ÷±ºÀÇ.
  • monoclonal
    ´ÜÀÏŬ·Ð¼º, ´ÜÀϼ¼Æ÷±ºÀÇ.
  • monoclonal
    ´ÜÀÏŬ·Ð¼º, ´ÜÀϼ¼Æ÷±ºÀÇ.
  • monoclonal antibody
    ´ÜÀÏŬ·Ð¼º Ç×ü(Ó¤ìé¡­àõ ù÷ô÷)
  • monoclonal gammopathy
    ´ÜÀÏŬ·Ð °¨¸¶º´Áõ(¡­Ü»ñø)
  • monoclonal gammopathy
    ´Ü(ÀÏ)Ŭ·Ð°¨¸¶º´Áõ.
  • monoclonal gammopathy
    ´Ü(ÀÏ)Ŭ·Ð°¨¸¶º´Áõ.
  • monoclonal gammopathy
    ´Ü(ÀÏ)Ŭ·Ð°¨¸¶º´Áõ.
  • monoclonal gammopathy
    ´Ü(ÀÏ)Ŭ·Ð°¨¸¶º´Áõ.
  • monoclonal immunoglobulin
    ´ÜÀÏŬ·Ð¸é¿ª±Û·ÎºÒ¸°
  • monoclonal immunoglobulin detection
    ´ÜÀÏŬ·Ð¸é¿ª±Û·ÎºÒ¸°°ËÃâ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • monoclonal antibodies
    ´Ü(Ó¤)Ŭ·Ð Ç×ü(ù÷ô÷)
  • acetate hypothesis
    ¾Æ¼¼Æ®»ê(ß«) ¼³(àã)
  • adapter hypothesis
    ¾Æ´äÅͼ³(àã)
  • adenylate charge hypothesis
    ¾Æµ¥´Ò»ê(ß«)´ëÀü¼³(Óáï³àã)
  • adenylate control hypothesis
    ¾Æµ¥´Ò»ê(ß«)Á¶Àý¼³(ðàï½àã)
  • Akabori hypothesis
    ¾ÆÄ«º¸¸®¼³(àã)
  • autocrine hypothesis
    ÀÚ°¡ºÐºñ¼³ (í»Ê«ÝÂÝôàã)
  • Belling's hypothesis
    º§¸µ¼³(àã)
  • biochemical coupling hypothesis
    »ýÈ­ÇÐÀû(ßæûùùÊîÜ) ¦ÁöÀ½¼³(àã)
  • biochemical deletion hypothesis
    »ýÈ­ÇÐÀû(ßæûùùÊîÜ)°á½Ç¼³(ÌÀã÷àã)
  • biogenic amine hypothesis
    »ýü(ßæô÷)¾Æ¹Î¼³(àã)
  • bookmark hypothesis
    ¼­Ç¥¼³(ßöøöàã)
  • catabolic deletion hypothesis
    ÀÌÈ­´ë»çÀû °á¼Õ¼³(ì¶ûùÓÛÞóîÜ ÌÀáßàâ)
  • chemical coupling hypothesis
    È­ÇÐ(ûùùÊ) Ä«Çøµ¼³(àã)
  • chemiosmotic coupling hypothesis
    È­ÇлïÅõ(ûùùÊß¶÷â) ¦ÁöÀ½¼³(àã)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • hypothesis
    °¡¼³
  • monoclonal
    ´ÜÀÏŬ·Ð¼º, ´ÜÀϼ¼Æ÷±ºÀÇ
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
H0 null hypothesis
H1 alternative hypothesis
LNH large number hypothesis
TRH tension-reducing hypothesis; thyrotropin-releasing hormone
MAbs Monoclonal Antibodies
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
(3)H hypothesis that
BMG benign monoclonal gammopathy
Bi-MAbs Bispecific monoclonal antibodies
BsMab Bispecific monoclonal antibody
HuMAbs Human monoclonal antibodies
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 10 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • monoclonal
    ´ÜºÐÁö¼º, ´ÜÀÏ Å¬·Ð¼º, ´ÜÀÏ ¼¼Æ÷¼º, ´ÜŬ·Ð¼º, ´ÜÀÏ ¼¼Æ÷±ºÀÇ
    ´ÜÀÏ ¼¼Æ÷¿¡¼­ À¯·¡µÈ.
  • monoclonal gammopathy
    ´Ü Ŭ·Ð °¨¸¶º´Áõ, ´ÜÀÏ Å¬·Ð °¨¸¶º´Áõ
  • monoclonal immunoglobulin detection
    ´ÜÀÏ Å¬·Ð ¸é¿ª ±Û·ÎºÒ¸° °ËÃâ
  • monoclonal theory
    ´ÜÀÏ ¼¼Æ÷ À¯·¡¼³
  • altered-self hypothesis
    º¯È­ÇÑ ÀÚ±â Ç׿ø °¡¼³
    T-B Çùµ¿ÀÛ¿ëÀ̳ª Killer T ¼¼Æ÷ÀÇ Ç¥Àû¼¼Æ÷ÀÇ ÀÎ½Ä ±â±¸¿¡ À־ ¸²ÇÁ±¸´Â ¹ÝÀÀÇÏ´Â »ó´ëÀÇ ±¸Á¶·Î¼­ ºñÀÚ±âÀÎ Ç׿ø°ú ÀÚ±âÀÎ MHCÀÇ ¾çÂÊÀ» ÀνÄÇϰí ÀÖ´Ù. ÀÌ °æ¿ì »ý°¢ÇÏ´Â ¹æ½Ä¿¡ µÎ °³ÀÇ ¹æ½ÄÀÌ ÀÖÀ¸¸ç ºñÀÚ±â¿Í ÀڱⰡ ÇϳªÀÇ °ÍÀ¸·Î¼­ ÇÑ Á¾·ùÀÇ ¼ö¿ëü¿¡ ÀÇÇÏ¿© ÀÎ½ÄµÈ´Ù°í »ý°¢ÇÏ´Â °ÍÀÌ º¯È­ÇÑ ÀÚ°¡ Ç׿ø °¡¼³ÀÇ »ý°¢ ¹æ½ÄÀÌ´Ù.
  • convergence-projection hypothesis
    ÆøÁÖ Åõ»ç °¡¼³
  • dual recognition hypothesis
    2Áß Àνļ³
    ¸é¿ª ¼¼Æ÷ »çÀÌÀÇ »óÈ£ ÀÛ¿ë¿¡ À־ÀÇ T ¼¼Æ÷ÀÇ ÀÎ½Ä ±â±¸¿¡ °üÇÑ °¡¼³ÀÇ Çϳª. T ¼¼Æ÷¿¡´Â ÀÚ±âÀÇ MHC ºÐÀÚ¸¦ ÀνÄÇϱâ À§ÇÑ ¼ö¿ëü¿Í ´Ù¸¥ °ÍÀ» ÀνÄÇϱâ À§ÇÑ ¼ö¿ëü°¡ °¢°¢ µ¶¸³ÇÏ¿© Á¸ÀçÇÑ´Ù°í ÇÏ´Â »ý°¢.
  • hypothesis
    °¡¼³
    ¸î °¡ÁöÀÇ Çö»óÀ» ¼³¸íÇÒ ¼ö ÀÖÀ¸¸ç Ãß·ÐÀ̳ª ½ÇÇèÀ» ±âÃÊ·Î ÇÏ¿© °¡Á¤µÈ ÃßÃø.
  • Starling's hypothesis
    ½ºÅ»¸µÀÇ °¡¼³
  • unitarian hypothesis
    Ç×ü µ¿Àϼ³
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
antibodies, monoclonal Antibodies produced by clones of cells such as those isolated after hybridization of activated b lymphocytes with neoplastic cells. These hybrids are often referred to as hybridomas.
(12 Dec 1998)
monoclonal 1. <cell biology> Used of a cell line whether within the body or in culture to indicate that it has a single clonal origin.
2. <immunology> Monoclonal antibodies are produced by a single clone of hybridoma cells and are therefore a single species of antibody molecule.
(18 Nov 1997)
monoclonal antibodies Identical antibodies that are made in large amounts in the laboratory. Doctors are studying ways of using monoclonal antibodies to treat leukaemia.
(12 Dec 1998)
monoclonal antibody <immunology, molecular biology> A substance, usually a protein, which can be synthsised in the laboratory in pure form by a single clone (population) of cells.
These antibodies can be made in large quantities and have a specific affinity for certain target molecules called antigens which can be found on the surface of cells and those that are malignant.
Monoclonal antibodies are currently being investigated as a possible form of cancer treatment although their benefit has not be fully proven.
(16 Dec 1997)
monoclonal gammopathies, benign Conditions characterised by the presence of a monoclonal serum (or urine) protein without clinical manifestations of plasma cell dyscrasia.
(12 Dec 1998)
monoclonal immunoglobulin A homogenous immunoglobulin resulting from the proliferation of a single clone of plasma cells and which, during electrophoresis of serum, appears as a narrow band or "spike"; it is characterised by heavy chains of a single class and subclass, and light chains of a single type.
Synonym: M protein, monoclonal protein, paraprotein.
(05 Mar 2000)
monoclonal peak A narrow band visible on electrophoresis or an abnormal arc seen on immunoelectrophoresis, thought to represent immunoglobulin of one cell clone.
(05 Mar 2000)
monoclonal protein A homogenous immunoglobulin resulting from the proliferation of a single clone of plasma cells and which, during electrophoresis of serum, appears as a narrow band or "spike"; it is characterised by heavy chains of a single class and subclass, and light chains of a single type.
Synonym: M protein, monoclonal protein, paraprotein.
(05 Mar 2000)
adaptor hypothesis A hypothesis, proposed by F.H.C. Crick, that an adaptor molecule must be present between the information-containing DNA and the protein being synthesised.
(05 Mar 2000)
altered self hypothesis The hypothesis that the T-cell receptor in MHC mediated phenomena recognises a syngeneic MHC Class I or Class II molecule after modification by a virus or certain chemicals.
See: MHC restriction.
(18 Nov 1997)
alternative hypothesis In Neyman-Pearson testing of a hypothesis, the hypothesis or family of hypotheses about the numerical value of a parameter if and only if the null hypothesis is rejected as untenable.
(05 Mar 2000)
autocrine hypothesis That tumour cells containing viral oncogenes may have encoded a growth factor, normally produced by other cell types, and thereby produce the factor autonomously, leading to uncontrolled proliferation.
(05 Mar 2000)
Avogadro's hypothesis <physics> The hypothesis that equal volumes of two different gases at the same temperature and pressure contain the same number of molecules.
(02 Jan 1998)
Bayesian hypothesis An array of surmised values of a parameter to be severally explored in the light of a current set of data, with logical symmetry being preserved among all. The merits of each hypothesis entertained are based on quantity, the prior probability. The probability of the data conditional on the hypothesis is computed as the conditional probability for each; the product of the two for each hypothesis is the joint probability, and the ratio of each joint probability to the sum of all the joint probabilities is the posterior probability for that hypothesis. Unlike the Neyman-Pearson test of hypotheses, the answer is a statement about the hypothesis, not about the sample conditional on the hypothesis. No hypothesis is preferred or prevails by default. The procedure may be applied recursively any number of times, as the data becomes available.
(05 Mar 2000)
Makeham's hypothesis A development of Gompertz' hypothesis as to the force of mortality following some mathematical law. Makeham assumed that death was the consequence of two generally coexisting causes: 1) chance; 2) a deterioration or increased inability to withstand destruction. The first of these is constant, the second is an increasing geometrical progression.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 6 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • monoclonal
    ´ÜÀÏ ¼¼Æ÷¿¡¼­ À¯·¡ÇÏ´Â ¼¼Æ÷ÀÎ(·Î ¸¸µé¾î Áö´Â)
  • monoclonal antibody
    ´ÜÀÏ Å¬·Ð Ç×ü
  • hypothesis
    °¡¼³
  • efficient market hypothesis
    (Áõ±Ç)È¿À²Àû ½ÃÀå °¡¼³(»õ·Î¿î Á¤º¸ÀÇ ÁÖ°¡¿¡ÀÇ ¹ÝÀÀÀº µ¿½ÃÀûÀ̶õ °¡¼³)
  • hypothesis
    °¡¼³;°¡Á¤
  • nebular hypothesis(theory)
    (õ)(žç°èÀÇ)¼º¿î¼³
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á